Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

ConditionsAtrial Fibrillation Supraventricular Arrhythmia Ventricular Arrhythmias and Cardiac Arrest Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorNorthwell Health

About this trial

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.

Eligibility criteria

Qualifiers

>18yo

Willing to sign and date consent form,

Willing to be remotely monitored

Initiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)

Disqualifiers

Documented AF/VA in past 12 months

Cerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past year

Has current implanted pulse generator, defibrillator, pacemaker, or resynchronization device

heart surgery within past 90 days

Trial design

Treatments tested in this trial

Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)

Treatment groups

50 Participants

are divided into 1 treatment group

Locations

Northwell (Northshore University/Long Island Jewish Hospitals)11040, New Hyde ParkNew York, United States

Sponsors and collaborators

Northwell Health

Lead sponsor

Source ClinicalTrials.gov